Biotech Acquisition Stock Forecast, Price & News

Wall Street analysts have given Biotech Acquisition a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Biotech Acquisition wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Some companies that are related to Biotech Acquisition include 378 (SCCB), ACE Convergence Acquisition (ACEVU), Ackrell SPAC Partners I (ACKIU), Adara Acquisition (ADRAU), Adit EdTech Acquisition (ADEXU), AEA-Bridges Impact (IMPXU), Aequi Acquisition (ARBGU), AF Acquisition Corp. Units (AFAQU), African Gold Acquisition (AGACU), Altimar Acquisition Corp. III (ATAQU), Altimeter Growth (AGCUU), Anzu Special Acquisition Corp I Units (ANZUU), Archimedes Tech SPAC Partners Co. Unit (ATSPU), ArcLight Clean Transition (ACTCU) and Ark Global Acquisition Corp. Unit (ARKIU).
View all of BIOTU's competitors.

Biotech Acquisition trades on the OTCMKTS under the ticker symbol "BIOTU."

Biotech Acquisition's lock-up period expires on Monday, July 26th. Biotech Acquisition had issued 20,000,000 shares in its initial public offering on January 26th. The total size of the offering was $200,000,000 based on an initial share price of $10.00. Shares of the company owned by major shareholders and company insiders will be eligible for trade following the end of the lock-up period.

Shares of BIOTU can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of BIOTU stock can currently be purchased for approximately $10.10.

The company can be reached via phone at 212 227 1905.